Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolcapone in Pathological Gambling
NCT02772978Phase 1Completed
- Sponsor
- University of California, San Francisco
- Start
- Aug 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of tolcapone in gambling disorder (GD), sponsored by University of California, San Francisco. Primary endpoint: Correlation Between the Impulsive Choice Ratio and Baseline Impulsivity (Barratt Impulsiveness Scale, Non-planning Subscale) at 120 minutes. Started Aug 2014; status: completed.
02
Drugs
tolcapone
03
Conditions
gambling disorder (GD)
Beyond the preview
Go deeper on NCT02772978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02772978.